TD Cowen Upgrades Genmab to Buy, Raises Price Target to $43

Benzinga Newsdesk www.benzinga.com Positive 88.6%

Neg 0% Neu 0% Pos 88.6%

TD Cowen analyst Yaron Werber upgrades Genmab (NASDAQ:GMAB) from Hold to Buy and raises the price target from $32 to $43.